According to the prospective study by Clifton et al [68], for patients with TN breast cancer with the BRCA1 and BRCA2 pathogenic variants in stage I/II, there was no difference in overall survival for those who received neoadjuvant chemotherapy compared with those who received adjuvant chemotherapy [68]. This evidence concerns the gene BRCA2 and breast cancer.